Showing 2551-2560 of 5976 results for "".
- New Allergan Aesthetics and Skinbetter Initiative Aims to Advance Health Equity and Diversity in Aestheticshttps://practicaldermatology.com/news/new-initiative-allergan-aesthetics-and-skinbetter-aims-to-advance-health-equity-and-diversity-in-aesthetics/2460526/Allergan Aesthetics, an AbbVie company, and Skinbetter Science have launched a new long-term, educational initiative—DREAM: Driving Racial Equity in Aesthetic Medicine—to further the principles of racial and ethnic diversity, inclusion, respect and understanding in the fields of derma
- Partner Therapeutics Moves Ahead with Phase 3 Study of Leukine Plus Ipilumimab and Nivolumab for Melanomahttps://practicaldermatology.com/news/partner-therapeutics-moves-ahead-with-phase-3-study-of-leukine-plus-ipilumimab-and-nivolumab-for-melanoma/2460524/Partner Therapeutics, Inc. is resuming enrollment in the National Cancer Institute (NCI)-sponsored ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) study of Leukine plus Ipilumimab and Nivolumab for Melanoma following a successful planned interim analysis. EA6141 (
- Revance Commercial Infrastructure to Launch RHA Collection of Dermal Fillershttps://practicaldermatology.com/news/revance-commercial-infrastructure-to-launch-rha-collection-of-dermal-fillers/2460512/Revance Therapeutics, Inc. will begin introducing the RHA Collection of dermal fillers, Resilient Hyaluronic Acid, and the HintMD financial technology platform, in the United States in September. The RHA Collection of derma
- ISDIN Sunscreen Survey: Just 37% of the US Population Protects Themselves from the Sun on a Daily Basishttps://practicaldermatology.com/news/isdin-sunscreen-survey-just-37-of-the-us-population-protects-themselves-from-the-sun-on-a-daily-basis/2460505/While half of the US population is aware of the importance of sun protection and state they use sun protection during sun exposure, only 37 percent are using it on a daily basis, according to new survey from ISDIN. In the s
- InMode Introduces the Morpheus8 Platform and the Morpheus8 Body Fractional Technologyhttps://practicaldermatology.com/news/inmode-introduces-the-morpheus8-platform-and-the-morpheus8-body-fractional-technology/2460501/InMode Ltd. is introducing the Morpheus8 Body handpiece and Morpheus8 Platform. Morpheus8 Body is a full-body fractional technology that delivers RF energy up to a thermal depth of 8mm (7mm pin depth + an additional 1mm thermal profile), with its
- Membership Has Its Privileges: RealSelf Rolls Out RealSelf Insider Programhttps://practicaldermatology.com/news/membership-has-its-privileges-realself-rolls-out-realself-insider-program/2460496/RealSelf is introducing RealSelf INSIDER, a new membership program that offers cash rewards for cosmetic treatments as well as exclusive perks, including free virtual consultatio
- Galderma Gives Back: Company Donates 1,200 Backpacks Filled with School Supplies to Northwest ISD Studentshttps://practicaldermatology.com/news/galderma-gives-back-company-donates-1200-backpacks-filled-with-school-supplies-to-northwest-isd-students/2460495/For the fifth consecutive year, Galderma donated backpacks filled with school supplies to Northwest Independent School District (NISD) students. This year, Galderma donated 1,200 backpacks for students in grades Kindergarten through 12, for a total of 6,105 backpacks donated since 2016.
- Mount Sinai Researcher Identifies Single Gene Biomarker to Differentiate Between Atopic Dermatitis and Psoriasishttps://practicaldermatology.com/news/mount-sinai-researcher-identifies-single-gene-biomarker-to-differentiate-between-atopic-dermatitis-and-psoriasis/2460472/Mount Sinai researchers have pinpointed a single gene biomarker, nitride oxide synthase 2 (NOS2) that can distinguish atopic dermatitis (AD) and psoriasis with 100 percent accuracy using adhesive tape strips, a non-invasive alternative to skin biopsy. The study, published in the Jou
- Tremfya is First IL-23 Inhibitor Approved for PsAhttps://practicaldermatology.com/news/tremfya-is-first-il-23-inhibitor-approved-for-psa/2460471/FDA has approved Tremfya® (guselkumab) from Janssen Pharmaceutical Companies of Johnson & Johnson for adult patients with active psoriatic arthritis (PsA). Tremfya is the first interleukin (IL)-23 approved for active PsA. The safety and efficacy of
- ISHRS: New Guidelines for Hair Restoration Surgery During COVID-19 Pandemichttps://practicaldermatology.com/news/ishrs-new-guidelines-for-hair-restoration-surgery-during-covid-19-pandemic-1/2460469/Hair restoration surgeries can proceed safely in the midst of the ongoing COVID-19 pandemic, the International Society of Hair Restoration Surgery (ISHRS) says. The organization has established suggested protocols for resuming hair restoration practices and offers patients guidance in f